Last reviewed · How we verify

NCT06245278

The Effect of Non-Surgical Periodontal Therapy on Inflammatory Bowel Disease

Completed NA Last updated 25 June 2025
What this trial tests

NA trial testing ELISA (Enzyme-Linked ImmunoSorbent Assay) in Periodontitis in 60 participants. Completed in 1 October 2024.

Timeline
1 January 2024
Primary endpoint
1 June 2024
1 October 2024

Quick facts

Lead sponsorBiruni University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date1 January 2024
Primary completion1 June 2024
Estimated completion1 October 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Biruni University

Who can join

Adults 18 to 65, any sex, with Periodontitis or Inflammatory Bowel Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inflammatory bowel disease (IBD) is a chronic and recurrent inflammatory disease of the gastrointestinal tract characterised by complex interactions between genetic susceptibility, environmental factors, microbiota and host immune response. It has two main forms, Crohn's disease (CD) and Ulcerative colitis (UC). The main mechanism of IBD pathogenesis is dysregulated host immune response to commensal microbiota and disruption of the balance of pro- and anti-inflammatory cytokines in genetically predisposed individuals. Periodontitis is a multifactorial inflammatory disease associated with dental biofilm resulting in the loss of periodontal supporting tissues and subsequently teeth. Although the occurrence of the disease depends on multifactorial factors, bacterial plaque is the primary etiological factor and various bacterial species found in plaque are responsible for initiating and maintaining the inflammatory and immune response in periodontal disease. Periodontal diseases are known to contribute to many systemic diseases/conditions or systemic disorders are known to affect periodontal disease. Although the relationship between IBD and periodontitis is based on the potential link between oral and intestinal microbiomes and host immunoinflammatory response, the pathological interactions between the two diseases have not yet been determined. From this point of view, the aim of our study was to investigate the effect of periodontal status on serum, saliva and gingival biomarkers (TIM-3, TNF-α, IL-6 and IL-17) in patients with IBD and to evaluate the relationship between these values and periodontal clinical parameters. This is the first study to examine TIM-3 levels in saliva, serum and gingival samples in patients with IBD and periodontitis with IBD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Impact of non-surgical periodontal therapy on biomarker levels in inflammatory bowel disease patients with periodontitis.
    Bulut H, Öğüt E, Nuriyev K, Beşışık F, et al · · 2026 · PMID 42216769 · DOI 10.1002/jper.70153

Verify or expand the search:

Other trials of ELISA (Enzyme-Linked ImmunoSorbent Assay)

Trials testing the same drug.

Other recruiting trials for Periodontitis

Currently open trials in the same condition.

Other Biruni University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06245278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing